Your browser doesn't support javascript.
loading
Risk of false pharmaceutical equivalence (non-equivalence) decisions due to measurement uncertainty.
de Godoy Bertanha, Maria Luiza; Lourenço, Felipe Rebello.
Afiliação
  • de Godoy Bertanha ML; Departamento de Farmácia, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, Av. Prof. Lineu Prestes, 580 - Bloco 15, CEP 05508-000, São Paulo, SP, Brazil.
  • Lourenço FR; Departamento de Farmácia, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, Av. Prof. Lineu Prestes, 580 - Bloco 15, CEP 05508-000, São Paulo, SP, Brazil. Electronic address: feliperl@usp.br.
J Pharm Biomed Anal ; 204: 114269, 2021 Sep 10.
Article em En | MEDLINE | ID: mdl-34303215
The pharmaceutical equivalence between test (generic or similar) and reference medicine is evaluated through in vitro quality tests involving multiple compliance parameters. Despite efforts to ensure the reliability of the analytical results obtained in the pharmaceutical equivalence studies, measurement uncertainties lead to a risk of false decisions. Thus, the aim of this work was to evaluate the measurement uncertainties associated with the analytical results obtained in the pharmaceutical equivalence studies of different pharmaceutical forms and to estimate the risks of false decisions in the evaluation of pharmaceutical equivalence. The measurement uncertainties associated with the test results were evaluated using the bottom-up and top-down approaches. The consumer's or producer's combined particular risks and combined total risks were estimated using the Monte Carlo method implemented in MS-Excel spreadsheet (available as supplemental material). Considering the seven pharmaceutical equivalence studies performed in this work, three studies were not conclusive (risk of false pharmaceutical equivalence decisions higher than 5 %). Moreover, we concluded pharmaceutical equivalence and pharmaceutical non-equivalence in one and three studies, respectively. The particular and total combined risks are useful to make decisions regarding the evaluation of pharmaceutical equivalence between the test (generic or similar) and reference medicines. Regulatory bodies and pharmaceutical equivalence centers are very interested in the estimation of the risks of false decisions, particularly to evaluate the quality of medicines that are not submitted to bioequivalence studies.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Medicamentos Genéricos Tipo de estudo: Etiology_studies / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Pharm Biomed Anal Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Medicamentos Genéricos Tipo de estudo: Etiology_studies / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Pharm Biomed Anal Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido